Search

Your search keyword '"Salud, Antonieta"' showing total 38 results
Start Over Author "Salud, Antonieta" Search Limiters Full Text
38 results on '"Salud, Antonieta"'

2. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

Author

Élez, Elena, Gómez-España, María Auxiliadora, Grávalos, Cristina, García-Alfonso, Pilar, Ortiz-Morales, María José, Losa, Ferrán, Díaz, Inmaculada Alés, Graña, Begoña, Toledano-Fonseca, Marta, Valladares-Ayerbes, Manuel, Polo, Eduardo, Salgado, Mercedes, Martínez de Castro, Eva, Safont, María José, Salud, Antonieta, Ruiz-Casado, Ana, Tabernero, Josep, Riesco, María del Carmen, Rodriguez-Ariza, Antonio, and Aranda, Enrique

Published
2022
Full Text
View/download PDF

4. Secreted Phospholipases A2: Drivers of Inflammation and Cancer.

Author

Hidalgo, Ivan, Sorolla, Maria Alba, Sorolla, Anabel, Salud, Antonieta, and Parisi, Eva

Subjects
PHOSPHOLIPASE A2, ARACHIDONIC acid, EXTRACELLULAR space, CANCER invasiveness, TUMOR microenvironment
Abstract

Secreted phospholipase 2 (sPLA2) is the largest family of phospholipase A2 (PLA2) enzymes with 11 mammalian isoforms. Each sPLA2 exhibits different localizations and specific properties, being involved in a very wide spectrum of biological processes. The enzymatic activity of sPLA2 has been well described; however, recent findings have shown that they could regulate different signaling pathways by acting directly as ligands. Arachidonic acid (AA) and its derivatives are produced by sPLA2 in collaboration with other molecules in the extracellular space, making important impacts on the cellular environment, being especially relevant in the contexts of immunity and cancer. For these reasons, this review focuses on sPLA2 functions in processes such as the promotion of EMT, angiogenesis, and immunomodulation in the context of tumor initiation and progression. Finally, we will also describe how this knowledge has been applied in the search for new sPLA2 inhibitory compounds that can be used for cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402

Author

Pesántez, David, primary, ten Hoorn, Sanne, additional, Machado, Isidro, additional, García-Albéniz, Xabier, additional, Rodríguez-Salas, Nuria, additional, Heredia-Soto, Victoria, additional, Viñal, David, additional, Pericay, Carles, additional, García-Carbonero, Rocio, additional, Losa, Ferran, additional, Alonso, Vicente, additional, Vera, Ruth, additional, Feliu Batlle, Jaime, additional, Gallego, Javier, additional, Salud, Antonieta, additional, Nogué, Miquel, additional, Layos, Laura, additional, Montagut, Clara, additional, Capdevila, Jaume, additional, Vermeulen, Louis, additional, Maurel, Joan, additional, and Fernandez-Martos, Carlos, additional

Published
2023
Full Text
View/download PDF

10. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.

Author

Pesántez, David, Hoorn, Sanne ten, Machado, Isidro, García-Albéniz, Xabier, Rodríguez-Salas, Nuria, Heredia-Soto, Victoria, Viñal, David, Pericay, Carles, García-Carbonero, Rocio, Losa, Ferran, Alonso, Vicente, Vera, Ruth, Batlle, Jaime Feliu, Gallego, Javier, Salud, Antonieta, Nogué, Miquel, Layos, Laura, Montagut, Clara, Capdevila, Jaume, and Vermeulen, Louis

Subjects
RECTAL cancer, NEOADJUVANT chemotherapy, AFLIBERCEPT, MAGNETIC resonance, PROGRESSION-free survival, CHEMORADIOTHERAPY
Abstract

Background The results of the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)-1402 phase II randomized trial suggested that adding aflibercept to modified fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) induction, followed by chemoradiation and surgery, could increase the pathological complete response (pCR) rate in patients with high-risk, locally advanced rectal cancer. Here we update results up to 3 years of follow-up and evaluate the predictive value of consensus molecular subtypes identified with immunohistochemistry (IHC). Methods Patients with magnetic resonance imaging–defined T3c-d and/or T4 and/or N2 rectal adenocarcinoma in the middle or distal third were randomly assigned to mFOLFOX6 induction, with aflibercept (mF+A; n   =   115) or without aflibercept (mF; n   =   65), followed by capecitabine plus radiotherapy and surgery. The risk local relapse, distant metastases, disease-free survival (DFS), and overall survival (OS) were estimated at 3 years. Selected samples were classified via IHC into immune-infiltrate, epithelial, or mesenchymal subtypes. Results mF+A and mF had 3-year DFS of 75.2% (95% confidence interval [CI] = 66.1% to 82.2%) and 81.5% (95% CI = 69.8% to 89.1%), respectively; 3-year OS of 89.3% (95% CI = 82.0% to 93.8%) and 90.7% (95% CI = 80.6% to 95.7%), respectively; 3-year cumulative local relapse incidences of 5.2% (95% CI = 1.9% to 11.0%) and 6.1% (95% CI = 1.7% to 15.0%), respectively; and 3-year cumulative distant metastases rates of 17.3% (95% CI = 10.9% to 25.5%) and 16.9% (95% CI = 8.7% to 28.2%), respectively. pCRs were achieved in 27.5% (n   =   22 of 80) and 0% (n   =   0 of 10) of patients with epithelial and mesenchymal subtypes, respectively. Conclusion Adding aflibercept to mFOLFOX6 induction was not associated with improved DFS or OS. Our findings suggested that consensus molecular subtypes identified with IHC subtypes could be predictive of pCR with this treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

Author

Valladares-Ayerbes, Manuel, primary, Garcia-Alfonso, Pilar, additional, Muñoz Luengo, Jorge, additional, Pimentel Caceres, Paola Patricia, additional, Castillo Trujillo, Oscar Alfredo, additional, Vidal-Tocino, Rosario, additional, Llanos, Marta, additional, Llorente Ayala, Beatriz, additional, Limon Miron, Maria Luisa, additional, Salud, Antonieta, additional, Cirera Nogueras, Luis, additional, Garcia-Carbonero, Rocio, additional, Safont, Maria Jose, additional, Falco Ferrer, Esther, additional, Aparicio, Jorge, additional, Vicente Conesa, Maria Angeles, additional, Guillén-Ponce, Carmen, additional, Garcia-Teijido, Paula, additional, Medina Magan, Maria Begoña, additional, Busquier, Isabel, additional, Salgado, Mercedes, additional, and Lloansí Vila, Ariadna, additional

Published
2022
Full Text
View/download PDF

12. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

Author

Grupo de Tratamiento de los Tumores Digestivos (España), Sanofi, Tabernero, Josep [0000-0002-2495-8139], Aranda, Enrique [0000-0002-5471-2842], Élez, Elena, Gómez-España, María Auxiliadora, Grávalos, Cristina, García-Alfonso, Pilar, Ortiz-Morales, María José, Losa, Ferrán, Alés Díaz, Inmaculada, Graña, Begoña, Toledano Fonseca, Marta, Valladares-Ayerbes, Manuel, Polo, Eduardo, Salgado, Mercedes, Martínez de Castro, Eva, Safont, María José, Salud, Antonieta, Ruiz-Casado, Ana, Tabernero, Josep, Riesco-Martínez, María del Carmen, Rodríguez-Ariza, Antonio, Aranda, Enrique, Grupo de Tratamiento de los Tumores Digestivos (España), Sanofi, Tabernero, Josep [0000-0002-2495-8139], Aranda, Enrique [0000-0002-5471-2842], Élez, Elena, Gómez-España, María Auxiliadora, Grávalos, Cristina, García-Alfonso, Pilar, Ortiz-Morales, María José, Losa, Ferrán, Alés Díaz, Inmaculada, Graña, Begoña, Toledano Fonseca, Marta, Valladares-Ayerbes, Manuel, Polo, Eduardo, Salgado, Mercedes, Martínez de Castro, Eva, Safont, María José, Salud, Antonieta, Ruiz-Casado, Ana, Tabernero, Josep, Riesco-Martínez, María del Carmen, Rodríguez-Ariza, Antonio, and Aranda, Enrique

Abstract

[Background] Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE)., [Methods] Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed., [Results] In total, 101 patients were followed for a median of 12 (6–17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was <1941 versus ≥1941 pg/mL (9 versus 4 months). Patients with VEGF-A < 1941 pg/mL showed longer median OS (19 versus 8 months), TTP (9 versus 4 months) and TTF (8 versus 4 months), along with higher ORR (26% versus 9%) and DCR (81% versus 55%). No differences were identified according to ACE levels., [Conclusions] This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes.

Published
2022

14. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

Author

Élez, Elena, primary, Gómez-España, María Auxiliadora, additional, Grávalos, Cristina, additional, García-Alfonso, Pilar, additional, Ortiz-Morales, María José, additional, Losa, Ferrán, additional, Díaz, Inmaculada Alés, additional, Graña, Begoña, additional, Toledano-Fonseca, Marta, additional, Valladares-Ayerbes, Manuel, additional, Polo, Eduardo, additional, Salgado, Mercedes, additional, Martínez de Castro, Eva, additional, Safont, María José, additional, Salud, Antonieta, additional, Ruiz-Casado, Ana, additional, Tabernero, Josep, additional, Riesco, María del Carmen, additional, Rodriguez-Ariza, Antonio, additional, and Aranda, Enrique, additional

Published
2021
Full Text
View/download PDF

16. El Registre poblacional de càncer a Lleida en zones urbanes i rurals. Resultats de l’any 2014

Author

Florensa, Dídac, Pedrol, Tere, Mòdol-Pena, Irminia, Farré, Xavier, Salud, Antonieta, Mateo, Jordi, Godoy, Pere, [Florensa D] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Hospital Universitari de Santa Maria de Lleida, Gestió de Serveis Sanitaris (GSS), Lleida, Spain. Departament d’Informàtica i Enginyeria Industrial, Universitat de Lleida, Lleida, Spain. [Pedrol T, Salud A] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Hospital Universitari Arnau de Vilanova de Lleida, Institut Català de la Salut, Generalitat de Catalunya, Lleida, Spain. [Mòdol I, Farré X] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain. [Mateo J] Departament d’Informàtica i Enginyeria Industrial, Universitat de Lleida, Lleida, Spain. [Godoy P] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain. Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain. Consorci Centre de Recerca Biomèdica en Xarxa d’Epidemiologia i Salut Pública (CIBERESP). Institut de Salut Carlos III, Madrid, Spain, and Departament de Salut

Subjects
Neoplasms [DISEASES], neoplasias [ENFERMEDADES], Lleida, Càncer - Pacients - Lleida (Catalunya) - Registres, Indicadors de salut, Registres hospitalaris - Lleida (Catalunya) - Estadístiques, Investigative Techniques::Epidemiologic Methods::Data Collection::Records::Hospital Records [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Lérida, técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros hospitalarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Abstract

Càncer; Registre; Epidemiologia; Salut pública Cáncer;: Registro; Epidemiología; Salud pública Cancer; Registry; Epidemiology; Public health Introducció. L’objectiu de l’article és descriure els resultats del Registre hospitalari de tumors de Lleida l’any 2014 i valorar l’aportació proporcional de casos al Registre poblacional de càncer de les zones rurals i urbanes de Lleida. Mètodes. Es va fer un estudi epidemiològic descriptiu dels casos de càncer de residents en zones urbanes i rurals de Lleida detectats pel Registre hospitalari de tumors de Lleida (Hospital Universitari Arnau de Vilanova de Lleida). Els casos es van registrar segons els criteris internacionals. Les fonts d’informació principals van ser les altes hospitalàries del CMBD (codis CIM-9 entre el rang 140.0 i el 208.9) i els informes d’anatomia patològica. Es van diferenciar les poblacions amb més de 10.000 habitants com a urbanes i la resta com a rurals, i tot seguit es van comparar les casos detectats entre els residents i els esperats d’aquestes zones segons les taxes crues del Registre poblacional de càncer de Catalunya. Resultats. Es van detectar 2.472 tumors, 1.473 (59,6%) en homes i 999 (40,4%) en dones. Es va fer la verificació histològica de 2.363 tumors (95,6%). La majoria de pacients, 2.239 (91,8%), corresponien a residents de Lleida. En els homes residents els tumors més freqüents van ser els de pròstata (243), còlon i recte (218), bufeta urinària (157) i pulmó (149). En les dones van ser els de mama (253), còlon i recte (148), leucèmia i mieloma (56) i cos uterí (52). Segons les taxes del Registre poblacional de Càncer de Catalunya es podien esperar 2.086 casos (1.236 en homes i 850 en dones). Els casos observats entre els homes en zones urbanes van ser 534 (cobertura del 96,6%) i entre les dones, 368 (cobertura del 93,2%). En les zones rurals, entre els homes van ser 639 (cobertura del 93,3%) i entre les dones, 464 (cobertura del 102%). Es van observar cobertures superiors al 100% en leucèmies (123,1% en zones urbanes i 176,5% en rurals), bufeta urinària (158 en zones urbanes i 125,8% en rurals) i còlon i recte (119,8% en zones urbanes i 107,5% en rurals) entre els homes; i en leucèmies (150% en zones urbanes i 200% en rurals), encèfal i SNC (185,7% en zones urbanes i 112,5 en rurals) i mama (103,5% en zones urbanes i 104,6% en rurals) entre les dones. Conclusions. El rànquing i les taxes de tumors en les diferents zones a Lleida suggereixen que el càncer presenta certes peculiaritats que haurien de ser investigades a partir del Registre poblacional de càncer a Lleida Introducción. El objetivo del artículo es describir los resultados del Registro hospitalario de tumores de Lleida el año 2014 y valorar la aportación proporcional de casos al Registro poblacional de cáncer de las zonas rurales y urbanas en Lleida. Métodos. Se llevó a cabo un estudio epidemiológico descriptivo de los casos de cáncer de residentes en zonas urbanas y rurales de Lleida detectados por el Registro hospitalario de tumores de Lleida (Hospital Universitario Arnau de Vilanova). Los casos fueron registrados según los criterios internacionales. Las fuentes de información fueron las altas hospitalarias del CMBD (códigos CIM-9 entre el rango 140.0 y el 208.9) y los informes de anatomía patológica. Se diferenciaron las poblaciones con más de 10.000 habitantes como urbanas y las otras como rurales, y a continuación se compararon los casos detectados entre los residentes y los esperados de estas zonas según las tasas crudas del Registro poblacional de cáncer de Cataluña. Resultados. Se detectaron 2.472 tumores, 1.473 (59,6%) en hombres y 999 (40,4%) en mujeres. Se verificaron histológicamente 2.363 tumores (95,6%). La mayoría de pacientes, 2.239 (91,8%), correspondían a residentes en Lleida. En los hombres residentes los tumores más frecuentes fueron los de próstata (243), colon y recto (218), vejiga urinaria (157) y pulmón (149). En las mujeres fueron los de mama (253), colon y recto (148), leucemia y mieloma (56) y cuerpo uterino (52). Según las tasas del Registro poblacional de cáncer de Cataluña se podían esperar 2.086 casos (1.236 en hombres y 850 en mujeres). Los casos observados entre los hombres en zonas urbanas fueron 534 (cobertura del 96,6%) y entre las mujeres 368 (cobertura del 93,2%). En las zonas rurales, entre los hombres fueron 639 (cobertura del 93,3%) y entre las mujeres, 464 (cobertura del 102%). Se observaron coberturas superiores al 100% en leucemias (123,1% en zonas urbanas y 176,5% en rurales), vejiga urinaria (158 en zonas urbanas y 125,8% en rurales) y colon y recto (119,8% en zonas urbanas y 107,5% en rurales) entre los hombres; y en leucemias (150% en zonas urbanas y 200% en rurales), encéfalo y SNC (185,7% en zonas urbanas y 112,5 en rurales) y mama (103,5% en zonas urbanas y 104,6% en rurales) entre las mujeres. Conclusiones. El ranking y las tasas de tumores en las diferentes zonas en Lleida sugieren que el cáncer presenta ciertas peculiaridades que deberían ser investigadas a partir del Registro poblacional de cáncer de Lleida. Introduction: The objective of this paper is to describe the results of Lleida’s Hospital-based Cancer Registry in 2014 and estimate the proportional contribution of cases to the populationbased cancer registry of the urban and rural areas in Lleida. Methods. A descriptive epidemiologic study of cancer cases resident in urban and rural areas in Lleida detected by Lleida’s Hospital-based Cancer Registry (Lleida’s Arnau de Vilanova University Hospital) was carried out. Cases were recorded according to international criteria. Main information sources were: hospital records CMBD (ICD-9 codes, 140.0 to 208.9) and reports of pathologic anatomy. Cases were classified by populations with more than 10,000 inhabitants as ‘urban populations’ and the other as ‘rural populations’. Residents and expected cases from these areas were compared according to the Catalan’s Population-based Cancer Registry crude rates. Results. 2,472 tumours – 1,473 (59.6%) in males and 999 (40.4%) in women – were detected, of which 2,363 (95.6%) were verified by histology. Most patients – 2,239 (91.8%) – corresponded to residents in Lleida. In men, most frequent tumours in residents were prostate (243), colon and rectum (218), urinary bladder (157) and lung (149); in women were breast (253), colon and rectum (148), leukaemia and myeloma (56), and uterine body (52). According to Catalan’s Population-based Cancer Registry rates, 2,086 cases (1,236 in men and 850 in women) could be expected. Observed cases among men in urban areas were 534 (96.6% coverage) and 368 (93.2% coverage) in women. In rural areas observed cases in men were 639 (93.3% coverage) and 464 (102%) in women. Coverage observed was higher than 100% in leukaemia (123.1% in urban areas and 176.5% in rural areas), urinary bladder (158% in urban areas and 125.8% in rural areas) and colon and rectum (119.8% in urban areas and 107.5% in rural areas) in men and leukaemia (150% in urban areas and 200% in rural areas), brain and central nervous system (185.7% in urban areas and 112.5% in rural areas), and breast (103.5% in urban areas and 104.6% in rural areas) in women.

Published
2021

19. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial

Author

Vidal, Joana, primary, Casadevall, David, additional, Bellosillo, Beatriz, additional, Pericay, Carles, additional, Garcia-Carbonero, Rocio, additional, Losa, Ferran, additional, Layos, Laia, additional, Alonso, Vicente, additional, Capdevila, Jaume, additional, Gallego, Javier, additional, Vera, Ruth, additional, Salud, Antonieta, additional, Martin-Richard, Marta, additional, Nogué, Miguel, additional, Cillán, Elena, additional, Maurel, Joan, additional, Faull, Iris, additional, Raymond, Victoria, additional, Fernández-Martos, Carlos, additional, and Montagut, Clara, additional

Published
2021
Full Text
View/download PDF

23. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

Author

Díaz-Serrano, Asunción, primary, Angulo, Barbara, additional, Dominguez, Carolina, additional, Pazo-Cid, Roberto, additional, Salud, Antonieta, additional, Jiménez-Fonseca, Paula, additional, Leon, Ana, additional, Galan, Maria Carmen, additional, Alsina, Maria, additional, Rivera, Fernando, additional, Plaza, J. Carlos, additional, Paz-Ares, Luis, additional, Lopez-Rios, Fernando, additional, and Gómez-Martín, Carlos, additional

Published
2018
Full Text
View/download PDF

24. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Author

Codony-Servat, Jordi, primary, Cuatrecasas, Miriam, additional, Asensio, Elena, additional, Montironi, Carla, additional, Martínez-Cardús, Anna, additional, Marín-Aguilera, Mercedes, additional, Horndler, Carlos, additional, Martínez-Balibrea, Eva, additional, Rubini, Michele, additional, Jares, Pedro, additional, Reig, Oscar, additional, Victoria, Iván, additional, Gaba, Lydia, additional, Martín-Richard, Marta, additional, Alonso, Vicente, additional, Escudero, Pilar, additional, Fernández-Martos, Carlos, additional, Feliu, Jaime, additional, Méndez, Jose Carlos, additional, Méndez, Miguel, additional, Gallego, Javier, additional, Salud, Antonieta, additional, Rojo, Federico, additional, Castells, Antoni, additional, Prat, Aleix, additional, Rosell, Rafael, additional, García-Albéniz, Xabier, additional, Camps, Jordi, additional, and Maurel, Joan, additional

Published
2017
Full Text
View/download PDF

26. Abstract P4-01-17: Expression of circulating tumor cells (CTC) and CK-19 mRNA (CK19) as prognostic factors in heavily pretreated metastatic breast cancer

Author

Morales, Serafin, primary, Velasco, Ana, additional, Vidal, Jose, additional, Serrate, Anna, additional, Valls, Joan, additional, Samame, Juan Carlos, additional, Gisbert, Rafael, additional, Moral, Desamparados, additional, Llombart, Antonio, additional, Salud, Antonieta, additional, and Matias-Guiu, Xavier, additional

Published
2015
Full Text
View/download PDF

27. Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer

Author

Feliu, Jaime, primary, Salud, Antonieta, additional, Safont, Maria J., additional, García-Girón, Carlos, additional, Aparicio, Jorge, additional, Losa, Ferran, additional, Bosch, Carlos, additional, Escudero, Pilar, additional, Casado, Enrique, additional, Jorge, Monica, additional, Bohn, Uriel, additional, Pérez-Carrión, Ramon, additional, Carmona, Alberto, additional, Custodio, Ana B., additional, and Maurel, Joan, additional

Published
2015
Full Text
View/download PDF

28. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Author

Fernandez-Plana, Julen, primary, Pericay, Carlos, additional, Quintero, Guillermo, additional, Alonso, Vicente, additional, Salud, Antonieta, additional, Mendez, Miguel, additional, Salgado, Mercedes, additional, Saigi, Eugeni, additional, and Cirera, Luis, additional

Published
2014
Full Text
View/download PDF

29. Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial

Author

Fernandez-Martos, Carlos, primary, Brown, Gina, additional, Estevan, Rafael, additional, Salud, Antonieta, additional, Montagut, Clara, additional, Maurel, Joan, additional, Safont, Maria Jose, additional, Aparicio, Jorge, additional, Feliu, Jaime, additional, Vera, Ruth, additional, Alonso, Vicente, additional, Gallego, Javier, additional, Martin, Marta, additional, Pera, Miguel, additional, Sierra, Enrique, additional, Serra, Javier, additional, Delgado, Salvadora, additional, Roig, Jose V., additional, Santos, Jesus, additional, and Pericay, Carles, additional

Published
2014
Full Text
View/download PDF

30. Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer

Author

Muñoz, Alberto, primary, Pericay, Carles, additional, García-Girón, Carlos, additional, Alonso, Vicente, additional, Dueñas, Rosario, additional, Cirera, Luis, additional, Rivera, Fernando, additional, Falcó, Esther, additional, Bustos, Iñaki Alvarez, additional, and Salud, Antonieta, additional

Published
2014
Full Text
View/download PDF

31. Preoperative Bevacizumab, Capecitabine and Oxaliplatin (CAPOX-B) in Intermediate Risk Rectal Adenocarcinoma, Selected by High Resolution MRI. Gemcad 0801 Study

Author

Carlos, Fernandez-Martos, primary, Gallen, Manuel, additional, Salud, Antonieta, additional, Pericay, Carles, additional, Maurel, Joan, additional, Safont, Maria Jose, additional, Aparicio, Jorge, additional, Feliu, Jaime, additional, Vera, Ruth, additional, Alonso-Orduna, Vicente, additional, Gallego, Javier, additional, Martin, Marta, additional, Estevan, Rafael, additional, and Brown, Gina, additional

Published
2013
Full Text
View/download PDF

32. P-0256 Phase II Study to Evaluate Efficacy and Safety of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (MCRC) Patients

Author

Alfonso, Pilar García, primary, Chaves, Manuel, additional, Muñoz, Andrés, additional, Salud, Antonieta, additional, García-Girón, Carlos, additional, Grávalos, Cristina, additional, Massutí, Bartomeu, additional, González-Flores, Encarnación, additional, Queralt, Bernardo, additional, López-Ladrón, Amelia, additional, Losa, Ferrán, additional, Oltra, Amparo, additional, Gómez, Ma José, additional, Campos, J. Manuel, additional, and Aranda, Enrique, additional

Published
2012
Full Text
View/download PDF

33. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.

Author

Garcia-Alfonso, Pilar, Chaves, Manuel, Muñoz, Andrés, Salud, Antonieta, García-Gonzalez, Maria, Grávalos, Cristina, Massuti, Bartomeu, González-Flores, Encarna, Queralt, Bernardo, López-Ladrón, Amelia, Losa, Ferran, Gómez, Maria Jose, Oltra, Amparo, and Aranda, Enrique

Subjects
COLON cancer treatment, IRINOTECAN, BEVACIZUMAB, METASTASIS, INTRAVENOUS therapy
Abstract

Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC. Methods: Patients received intravenous irinotecan 175 mg/m² on day 1 and oral capecitabine 1000 mg/m² (800 mg/m² for patients >65 years of age) twice daily on days 2-8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks. Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1-11. Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

34. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).

Author

Fernandez-Plana, Julen, Pericay, Carlos, Quintero, Guillermo, Alonso, Vicente, Salud, Antonieta, Mendez, Miguel, Salgado, Mercedes, Saigi, Eugeni, and Cirera, Luis

Subjects
CETUXIMAB, COLON cancer treatment, METASTASIS, DRUG efficacy, MEDICATION safety, OXALIPLATIN, FOLINIC acid, CLINICAL trials, THERAPEUTICS
Abstract

Background This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer. Methods Previously untreated patients with wild-type KRAS tumours received biweekly cetuximab (500 mg/m² on day 1) plus FOLFOX-4 (oxaliplatin 85 mg/m ² on day 1, leucovorin 200 mg/m² on days 1 and 2, and fluorouracil as a 400 mg/m² bolus followed by a 22-hour 600 mg/m² infusion on day 1 and 2). Treatment was continued until disease progression, onset of unacceptable toxicities, metastases surgery, or discontinuation request. The primary endpoint was ORR. Results The intention-to-treat population included 99 patients with a median age of 64.1 years (range, 34-82). The ORR was 60.6% (95%CI, 50.3% to 70.3%). The median follow-up was 17.8 months; the median OS and PFS were 20.8 and 10.1 months, respectively. Metastases from colorectal cancer were surgically resected in 26 (26.3%) patients, with complete resection achieved in 18 (69.2%) patients. Median PFS and OS in patients undergoing metastatic resection were 12.6 and 29.5 months, respectively. The most common grade 3-4 toxicities were neutropenia (32.3%), acne-like rash (15.2%) and diarrhoea (11.1%). Conclusions The efficacy of the biweekly combination of cetuximab with FOLFOX-4 in patients with wild-type KRAS tumours supports the administration of cetuximab in a dosing regimen more convenient for patients and healthcare providers. The activity of the biweekly administration is similar to what has been reported for the weekly regimen. Reported toxicity was also consistent with the known toxicity profile of weekly cetuximab. Trial registration EudraCT Number 200800690916 [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

36. Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging--Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study.

Author

Nogué, Miguel, Salud, Antonieta, Vicente, Pilar, Arriví, Antonio, Roca, José María, Losa, Ferran, Ponce, José, Safont, María José., Guasch, Inmaculada, Moreno, Isabel, Ruiz, Ana, and Pericay, Carles

Subjects
CANCER treatment, ANTINEOPLASTIC agents, THERAPEUTIC use of monoclonal antibodies, EPITHELIUM, RECTAL surgery, ADENOCARCINOMA, COMBINED modality therapy, COMPUTER software, CONFIDENCE intervals, HEALTH outcome assessment, PREOPERATIVE care, RECTUM tumors, RESEARCH funding, SURVIVAL analysis (Biometry), TUMOR classification, DATA analysis, TREATMENT effectiveness, SURGERY, TUMOR treatment
Abstract

Background. Concomitant chemoradiotherapy followed by total mesorectal excision is standard treatment for locally advanced rectal cancer. This approach, however, focuses on local disease control and delays systemic treatment. Induction chemotherapy has the advantage of earlier administration of systemic therapy and may improve distant control. The objective of the current study was to assess the efficacy and toxicity of adding bevacizumab to induction chemotherapy followed by preoperative bevacizumab-based chemoradiotherapy in patients with locally advanced rectal cancer. Patients and Methods. Eligible patients had high-risk rectal adenocarcinoma defined by magnetic resonance imaging criteria. Treatment consisted of four 21-day cycles of bevacizumab (7.5 mg/kg) and XELOX (capecitabine plus oxaliplatin), followed by concomitant radiotherapy (50.4 Gy) plus bevacizumab (5 mg/kg every 2 weeks) and capecitabine (825 mg/m2 twice daily on days 1-15). Surgery was scheduled for 6-8 weeks after chemoradiotherapy. The primary endpoint was pathologic complete response (pCR). Results. Between July 2007 and July 2008, 47 patients were recruited. Among 45 patients who underwent surgery, pCR was achieved in 16 patients (36%; 95% confidence interval: 22.29%-51.27%), and an additional 17 patients (38%) had Dworak tumor regression grade 3. R0 resection was performed in 44 patients (98%). Most grade 3/4 adverse events occurred during the induction phase and included diarrhea (11%), asthenia (4%), neutropenia (6%), and thrombocytopenia (4%). Eleven patients (24%) required surgical reintervention. Conclusions. Addition of bevacizumab to induction chemotherapy and chemoradiotherapy is feasible, with impressive activity and manageable toxicity. However, caution is recommended regarding surgical complications. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

37. El Registre poblacional de càncer a Lleida: resultats i perspectives

Author

Pedrol, Tere, Mòdol-Pena, Irminia, Salud, Antonieta, Godoy, Pere, [Godoy-Garcia, Pere] Registre poblacional de càncer a Lleida (REC Lleida), Departament de Salut, Generalitat de Catlunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain. Institut de Recerca Biomèdica de Lleida (IRB LLeida), Universitat de Lleida, Lleida, Spain. [Pedrol, Tere] Registre poblacional de càncer a Lleida (REC Lleida), Departament de Salut, Generalitat de Catlunya, Lleida, Spain. Hospital Universitari Arnau de Vilanova de Lleida, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Mòdol-Pena, Irminia] Registre poblacional de càncer a Lleida (REC Lleida), Departament de Salut, Generalitat de Catlunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain. [Salud, Antonieta] Registre poblacional de càncer a Lleida (REC Lleida), Departament de Salut, Generalitat de Catlunya, Lleida, Spain. Hospital Universitari Arnau de Vilanova de Lleida, Institut Català de la Salut (ICS), Lleida, Spain, and Departament de Salut

Subjects
Neoplasms [DISEASES], Investigative Techniques::Epidemiologic Methods::Data Collection::Records as Topic::Hospital Records [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Lleida, Técnicas de Investigación::Métodos Epidemiológicos::Recolección de Datos::Registros como Asunto::Registros de Hospitales [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Càncer - Pacients - Lleida - Registres, Neoplasias [ENFERMEDADES], Lérida, técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros hospitalarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Abstract

Càncer; Registre; Epidemiologia; Salut pública Cáncer; Registro; Epidemiologia; Salud Pública Cancer; Registy; Epidemiology; Public health Introducció: L’objectiu va ser descriure els resultats del Registre hospitalari de tumors de Lleida l’any 2012 i valorar la contribució proporcional de casos al Registre poblacional de càncer a Lleida. Mètodes: Es va realitzar un estudi epidemiològic descriptiu dels casos de càncer de residents a Lleida detectats pel Registre hospitalari de tumors de Lleida (Hospital Universitari Arnau de Vilanova de Lleida). Els casos es van registrar segons els criteris internacionals. Les fonts d’informació van ser: les altes hospitalàries del CMBD (codis CIM-9-MC entre el rang 140.0 i el 208.9), els informes d’anatomia patològica i el Registre de pacients d’Hematologia. Es van comparar els casos detectats en els residents i els esperats segons les taxes crues del Registre poblacional de càncer a Tarragona. Resultats: Es van detectar 1.922 tumors, 1.150 (59,8%) en homes i 772 (40,2%) en dones. Es va fer la verificació histològica de 1.772 tumors (92,2%). La majoria de pacients, 1.765 (93,3%), corresponien a residents a Lleida. En els homes residents els tumors més freqüents van ser els de còlon i recte (190), pròstata (180) i pulmó (144). En les dones van ser els de mama (218), còlon i recte (118) i de càncer de pell no melanoma (62). Segons les taxes del Registre poblacional de càncer a Tarragona es podien esperar 2.126 casos (1.310 en homes i 816 en dones). Els casos observats entre els homes van ser 941 (cobertura del 71,8%) i en les dones, 668 (cobertura del 81,9%). Es van observar cobertures superiors al 100% en els tumors de ronyó (153,3%), leucèmies (104,7%) i pàncrees (104%) entre els homes i en els de pulmó (134,4%), sistema nerviós central (121,4%) i ronyó (120% ) entre les dones. Conclusions: El rànquing de tumors a les comarques de Lleida suggereix que el càncer presenta certes peculiaritats que haurien de ser investigades a partir del Registre poblacional de càncer a Lleida. Introducción: El objetivo fue describir los resultados del Registro hospitalario de tumores de Lleida en el año 2012 y valorar la contribución proporcional de casos en el Registro poblacional de cáncer en Lleida. Métodos: Se llevó a cabo un estudio epidemiológico descriptivo de casos de cáncer de residentes en Lleida que fueron detectados por el Registro hospitalario de tumores de Lleida (Hospital Universitario Arnau de Vilanova de Lleida). Los casos fueron registrados según los criterios internacionales. Las fuentes de información fueron: las altas hospitalarias del CMBD (códigos CIE-9-MC entre el rango 140.0 y el 208,9), los informes de anatomía patológica y el Registro de pacientes de Hematología. Se compararon los casos detectados entre los residentes y los esperados según las tasas crudas del Registro poblacional de cáncer en Tarragona. Resultados: Se detectaron 1.922 tumores, 1.150 (59,8%) en hombres y 772 (40,2%) en mujeres. Se realizó la verificación histológica de 1.772 tumores (92,2%). La mayoría de pacientes, 1.765 (93,3%), correspondían a residentes en Lleida. En los hombres residentes los tumores más frecuentes fueron los de colon y recto (190), próstata (180) y pulmón (144). En las mujeres fueron los de mama (218), colon y recto (118) y de cáncer de piel no melanoma (62). Según las tasas del Registro poblacional de cáncer en Tarragona se podrían esperar 2.126 casos (1.310 en hombres y 816 en mujeres). Los casos observados entre los hombres fueron 941 (cobertura del 71,8%) y entre las mujeres, 668 (cobertura del 81,9%). Se observaron coberturas superiores al 100% en los tumores de riñón (153,3%), leucemia (104,7%) y páncreas (104%) entre los hombres y en los de pulmón (134,4%), sistema nervioso central (121,4%) y riñón (120%) entre las mujeres. Conclusiones: El ranking de tumores en las comarcas de Lleida sugiere que el cáncer presenta ciertas particularidades que deberían ser investigadas a partir del Registro poblacional de càncer en Lleida. Introduction: The objective was to describe the results of Lleida’s hospital tumor registry in the year 2012 and estimate the proportional contribution of these cases in the Lleida’s population- based cancer registry. Methods: A descriptive epidemiologic study of cancer cases living in Lleida that were detected by Lleida’s hospital tumor registry (Arnau de Vilanova University Hospital, Lleida) was carried out. The cases were recorded according to the international criteria. The sources of information were: discharge records at the minimum basic data set (CMDB) (ICD-9-CM codes, 208,9-140.0 ranks), pathological anatomy reports, and the hematology patient registry. Cases identified among the residents and those expected according to Tarragona’s population-based cancer registry crude rates were compared. Results:1,922 tumors were detected, 1,150 (59.8%) in males and 772 (40,2%) in women. Histological verification of 1,772 tumors (92.2%) was carried out. Most patients, 1,765 (93.3%), corresponded to residents in Lleida. In resident men, most frequent tumors were colon and rectum (190), prostate (180) and lung (144).In women were breast (218), colon and rectum (118) and non- melanoma skin cancer (62). According to Tarragona’s population-based cancer registry rates, 2,126 cases (1,310 in men and 816 in women) might be expected. Observed cases among men were 941 (71.8% coverage) and 668 in women (81.9% coverage). A coverage greater than 100% was observed for kidney (153,3), leukemia (104.7%) and pancreas (104%) in men and for lung (134,4%), brain (121,4%) and kidney (120%) in women. Conclusions: The ranking of tumors in Lleida regions suggests that cancer presents certain particularities that should be investigated from Lleida’s population-based cancer registry.

38. El registre poblacional de càncer a Lleida: resultats de l’any 2013

Author

Godoy, Pere, Pedrol, Tere, Mòdol-Pena, Irminia, Salud, Antonieta, [Godoy-Garcia P] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain. Institut de Recerca Biomèdica de Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain. Consorci Centre de Recerca Biomèdica en Xarxa d’Epidemiologia i Salut Pública (CIBERESP). Institut de Salut Carlos III, Madrid, Spain. [Pedrol T, Salud A]Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Hospital Universitari Arnau de Vilanova de Lleida. Institut Català de la Salut, Generalitat de Catalunya, Lleida, Spain. [Mòdol-Pena I] Registre poblacional de càncer de Lleida (REC Lleida), Departament de Salut, Generalitat de Catalunya, Lleida, Spain. Servei de Vigilància Epidemiològica i Resposta a les Emergències de Salut Pública de Lleida, Alt Pirineu i Aran, Agència de Salut Pública de Catalunya, Generalitat de Catalunya, Lleida, Spain, and Departament de Salut

Subjects
Neoplasms [DISEASES], Lleida, Environment and Public Health::Public Health::Epidemiologic Methods::Data Collection::Records as Topic::Hospital Records [HEALTH CARE], ambiente y salud pública::salud pública::métodos epidemiológicos::recopilación de datos::registros::registros hospitalarios [ATENCIÓN DE SALUD], Càncer - Pacients - Lleida (Catalunya) - Registres, Indicadors de salut, Registres hospitalaris - Lleida (Catalunya) - Estadístiques, Neoplasias [ENFERMEDADES], Medio Ambiente y Salud Pública::Salud Pública::Métodos Epidemiológicos::Recolección de Datos::Registros como Asunto::Registros de Hospitales [ATENCIÓN DE SALUD], Lérida
Abstract

Càncer; Registre; Epidemiologia; Salut pública Cáncer;: Registro; Epidemiología; Salud pública Cancer; Registry; Epidemiology; Public health Introducció. L’objectiu de l’article és descriure els resultats del Registre hospitalari de tumors de Lleida l’any 2013 i valorar l’aportació proporcional de casos al Registre poblacional de càncer a Lleida. Mètodes. Es va fer un estudi epidemiològic descriptiu dels casos de càncer de residents a Lleida detectats pel Registre hospitalari de tumors de Lleida (Hospital Universitari Arnau de Vilanova de Lleida). Els casos es van registrar segons els criteris internacionals. Les fonts d’informació van ser les altes hospitalàries del CMBD (codis CIM-9 entre el rang 140.0 i el 208.9) i els informes d’anatomia patològica. Es van comparar els casos detectats entre els residents i els esperats segons les taxes crues del Registre poblacional de càncer de Catalunya. Resultats. Es van detectar 2.028 tumors, 1.184 (58,3%) en homes i 844 (41%) en dones. Es va fer la verificació histològica de 1.939 tumors (95,6%). La majoria de pacients, 1.884 (93,8%), corresponien a residents a Lleida. En els homes residents els tumors més freqüents van ser els de pròstata (185), còlon i recte (179) i pulmó (136). En les dones van ser els de mama (227), còlon i recte (112) i cos uterí (44). Segons les taxes del Registre poblacional de Càncer de Catalunya es podien esperar 2.102 casos (1.248 en homes i 854 en dones). Els casos observats entre els homes van ser 1.108 (cobertura del 88,7%) i entre les dones, 795 (cobertura del 93,1%). Es van observar cobertures superiors al 100% en leucèmies (163,3%), melanomes de pell (116,6%) i pàncrees (109,7%) entre els homes; i en leucèmies (154,5%), melanomes de pell (116,7%) i tiroides (104,5%) entre les dones. Conclusions. El rànquing de tumors a les comarques de Lleida suggereix que el càncer presenta certes peculiaritats que haurien de ser investigades a partir del Registre poblacional de càncer a Lleida. Introducción. El objetivo del artículo es describir los resultados del Registro hospitalario de tumores de Lleida en el año 2013 y valorar la aportación proporcional de casos al Registro poblacional de cáncer en Lleida. Métodos. Se llevó a cabo un estudio epidemiológico descriptivo de los casos de cáncer de residentes en Lleida detectados por el Registro hospitalario de tumores de Lleida (Hospital Universitario Arnau de Vilanova de Lleida). Los casos fueron registrados según los criterios internacionales. Las fuentes de información fueron las altas hospitalarias del CMBD (códigos CIE-9 entre el rango 140.0 y el 208.9) y los informes de anatomía patológica. Se compararon los casos detectados entre los residentes y los esperados según las tasas crudas del Registro poblacional de cáncer de Cataluña. Resultados. Se detectaron 2.028 tumores, 1.184 (58,3%) en hombres y 844 (41%) en mujeres. Se verificaron histológicamente 1.939 tumores (95,6%). La mayoría de pacientes 1.884 (93,8%) correspondían a residentes en Lleida. En los hombres residentes los tumores más frecuentes fueron los de próstata (185), colon y recto (179) y pulmón (136). En las mujeres fueron los de mama (227), colon y recto (112) y cuerpo uterino (44). Según las tasas del Registro poblacional de cáncer de Cataluña se podían esperar 2.102 casos (1.248 en hombres y 854 en mujeres). Los casos observados entre los hombres fueron 1.108 (cobertura del 88,7%) y entre las mujeres, 795 (cobertura del 93,1%). Se observaron coberturas superiores al 100% en leucemias (163,3%), melanomas (116,6%) y páncreas (109,7%) entre los hombres; y leucemias (154,5%), melanomas (116,7%) y tiroides (104,5%) entre las mujeres. Conclusiones. El ranking de tumores en las comarcas de Lleida sugiere que el cáncer presenta ciertas particularidades que deberían ser investigadas a partir del Registro poblacional de cáncer en Lleida. Background. The objective of this paper is to describe the results of Lleida’s Hospital-based Cancer Registry in 2013 and estimate the proportional contribution of cases to the populationbased cancer registry. Methods. A descriptive epidemiologic study of cancer cases living in Lleida detected by Lleida’s Hospital-based Cancer Registry (Lleida’s Arnau de Vilanova University Hospital) was carried out. Cases were recorded according to international criteria. Information sources were: hospital records CMDB (ICD-9 codes-140.0 to 208.9) and reports of pathologic anatomy. Cases observed among the residents and cases expected by Catalan’s Population-based Cancer Registry crude rates were compared. Results. 2,028 tumours – 1,184 (58.3%) in males and 844 (41%) in women – were detected, of which 1,939 (95.6%) were verified by histology. Most patients – 1,884 (93.8%) –corresponded to residents in Lleida. In men, most frequent tumours in residents were prostate (185), colon and rectum (179) and lung (136); in women were breast (227), colon and rectum (112) and uterine body (44). According to Catalan's Population-based Cancer Registry rates, 2,102 cases (1,248 in men and 854 in women) could be expected. Observed cases among men were 1,108 (88.7% coverage) and 795 in women (93.1% coverage). Coverage observed was higher than 100% in leukaemia (163.3%), melanoma skin (116.6%) and pancreas (109.7%) in men and leukaemia (154.5%), melanoma skin (116.7%) and thyroid (104.5%) in women. Conclusions. Tumour ranking in Lleida regions suggests that cancer presents certain particularities that should be investigated based on Lleida’s Population-based Cancer Registry.

Catalog

Books, media, physical & digital resources
See catalog results